30 Hits in 1.2 sec

Evaluating the ASTHMAXcel Mobile Application Regarding Asthma Knowledge and Clinical Outcomes

Brian C Hsia, Sammy Wu, Wenzhu B Mowrey, Sunit P Jariwala
2020 Respiratory care  
We sought to longitudinally assess the efficacy of the patient-facing ASTHMAXcel mobile application in improving asthma knowledge and outcomes in adults with asthma. ASTHMAXcel is a novel smartphone application consistent with the National Asthma Education and Prevention Program, Global Initiative for Asthma, and British Thoracic Society/Scottish Intercollegiate Guidelines Network guidelines. The intervention was provided for 1-time use at baseline only. The Asthma Knowledge Questionnaire
more » ... the Asthma Control Test (ACT), and the mini-Asthma Quality of Life Questionnaire (mini-AQLQ) were administered at baseline and at 2, 4, and 6 months thereafter. Rates of asthma-related emergency department visits, hospitalizations, and prednisone use were also evaluated. ACT scores increased significantly at 2, 4, and 6 months (mean scores: 15.1 vs 16.9, P = .038; 15.1 vs 17.2, P = .02; 15.1 vs 17.9, P = .003) after baseline. There were significant increases in AKQ scores at 4 and 6 months (11.7 vs 12.6, P = .02; 11.7 vs 13.1, P = .005) and in mini-AQLQ scores at 6 months (55.5 vs 64.2, P = .02). There were significant decreases in asthma-related emergency department visits at 6 months (0.6 vs 0, P < .001) and in hospitalizations at 4 and 6 months (0.3 vs 0.1, P = .02; 0.3 vs 0, P = .002). Prednisone use decreased at 4 and 6 months (1.2 vs 0.6, P = .01; 1.2 vs 0.3, P < .001). ASTHMAXcel contributes to improved asthma knowledge and outcomes and to decreased health care utilization. ASTHMAXcel is an inexpensive, scalable aid for out-patient asthma management.
doi:10.4187/respcare.07550 pmid:32487751 fatcat:cxoqh4o5dfbspfygwvjkf7j7nu

AMFAST_Scoring_and_Instructions – Supplemental material for Validation of the Attention, Memory, and Frontal Abilities Screening Test (AMFAST)

Bryan M. Freilich, Nicole Feirsen, Elise I. Welton, Wenzhu B. Mowrey, Tamar B. Rubinstein
2019 Figshare  
Welton, Wenzhu B. Mowrey and Tamar B. Rubinstein in Assessment  ... 
doi:10.25384/sage.7575989 fatcat:nxbkiq46b5f6ljygrgg3iultny

Not all that glitters is gold: A guide to critical appraisal of animal drug trials in epilepsy

Aristea S. Galanopoulou, Wenzhu B. Mowrey
2016 Epilepsia Open  
Preclinical studies have produced numerous drugs with antiseizure properties that currently are the standard of care. One third of the human population with epilepsy still continues to have seizures despite the ongoing discoveries. The recognized clinical gaps of care that need to be addressed are the identification of antiepileptogenic and disease-modifying treatments, and treatments for refractory seizures or for seizures and epilepsies with limited or unsatisfactory treatments, such as early
more » ... life epileptic encephalopathies. In this invited review, we provide a historical summary of the international efforts to reevaluate the strategies adopted in preclinical epilepsy therapy discovery studies. We discuss issues that may affect the quality, interpretation, and validation of preclinical studies and their translation to successful therapies for humans affected with epilepsy. These include the selection of animal models and the study design; research practices that affect rigor (such as appropriate use of statistics and reporting of study methods and results, their validation across models, labs, and preclinical-clinical studies); the need to harmonize research methods and outcome assessment; and the importance of improving translation to clinically appropriate situations. The epilepsy research community is incrementally adopting collaborative research, including consortia or multicenter studies to meet these needs. Improving the infrastructure that can support these efforts will be instrumental in future success.
doi:10.1002/epi4.12021 pmid:28497130 pmcid:PMC5421644 fatcat:xenbhwwt35edpnlutzmkwbqjai

Associations of Dysnatremia with COVID-19 status and Mortality

Diane Liu, Wenzhu Mowrey, Molly Fisher, Abby Basalely, John McCarthy, Neelja Kumar, Jyotsana Thakkar, Yorg Azzi, Maureen Brogan, Ladan Golestaneh, Kimberly J Reidy, Wei Chen
2022 Kidney360  
Wenzhu Mowrey: Formal analysis; Investigation; Methodology. Molly Fisher: Conceptualization; Investigation; Methodology; Writing -review and editing.  ...  Mowrey reports the following: Ownership Interest: Google. M. Fisher reports the following: Honoraria: American Academy of HIV Medicine. L.  ... 
doi:10.34067/kid.0001062022 fatcat:eo3tcyhnljfs7o4qe7g46h5xr4

CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms

Stephen W. Briggs, Wenzhu Mowrey, Charles B. Hall, Aristea S. Galanopoulou
2013 Epilepsia  
Objective-Infantile spasms (IS) have poor outcomes and limited treatment options, including vigabatrin, a GABA aminotransferase inactivator. Vigabatrin has been associated with retinal toxicity. A high affinity vigabatrin analogue (CPP-115, Catalyst Pharmaceutical Partners) has shown lower risk of retinal toxicity. Here, we test the efficacy of CPP-115 in reducing spasms and its tolerability in the multiple-hit rat model of IS, in which daily vigabatrin reduced spasms only for one day, but was
more » ... ot well tolerated. Methods-Male rats were treated with the protocol of the multiple-hit model of IS at postnatal day 3 (PN3). Using a randomized, blinded, vehicle-controlled, dose-response study design, CPP-115 [0.1, 1, or 5 mg/kg intraperitoneally (i.p.)] or vehicle were given daily (PN4-12) or as single injection (PN7) after spasms onset. Intermittent video-or video-EEG monitoring was done. Secondary endpoints included: daily weights, survival, performance on open field activity, surface righting time, and negative geotaxis (PN3-20), horizontal bar (PN13-20), Barnes maze (PN16-19). Statistics used a linear mixed model of raw or normalized log-transformed data, taking into account the repeated observations on each animal. Results- The lower CPP-115 doses (0.1-1 mg/kg/day, PN4-12) reduced spasms between PN6-7 without increasing mortality. CPP-115 at 5 mg/kg/day (PN4-12) reduced spasms earlier (PN5), but was eventually lethal. A single CPP-115 injection (1mg/kg i.p.) decreased electroclinical spasms acutely but transiently. CPP-115 transiently improved the probability to >50% reduction of
doi:10.1111/epi.12424 pmid:24321005 pmcid:PMC4102583 fatcat:ggkbcu27vjc4xavixxtv46jhoe

Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease

Maria Salgado Guerrero, Alejandra Londono Jimenez, Chrisanna Dobrowolski, Wenzhu B. Mowrey, Beatrice Goilav, Shudan Wang, Anna Broder
2020 BMC Nephrology  
Background SLE manifestations after ESRD may be underdiagnosed and undertreated, contributing to increased morbidity and mortality. Whether specific symptoms persist after ESRD or a shift towards new manifestations occurs has not been extensively studied, especially in the non-Caucasian patients in the United States. In addition, hydroxychloroquine (HCQ) prescribing patterns post-ESRD have not been described. The objective of this study was to assess lupus activity and HCQ prescribing before
more » ... after ESRD development. Knowledge gained from this study may aid in the identification of SLE manifestations and improve medication management post-ESRD. Methods We performed a retrospective cohort study of SLE patients with incident ESRD between 2010 and 2017. SLE-related symptoms, serologic markers of disease activity, and medication use were collected from medical records before and after ESRD development. Results Fifty-nine patients were included in the study. Twenty-five (43%) patients had at least one clinical (non-renal) SLE manifestation documented within 12 months before ESRD. Of them, 11/25 (44%) continued to experience lupus symptoms post-ESRD; 9 patients without clinical or serological activity pre-ESRD developed new symptoms of active SLE. At the last documented visit post-ESRD, 42/59 (71%) patients had one or more clinical or serological markers of lupus activity; only 17/59 (29%) patients achieved clinical and serological remission. Thirty-three of 59 (56%) patients had an active HCQ prescription at the time of ESRD. Twenty-six of the 42 (62%) patients with active SLE manifestations post-ESRD were on HCQ. Patients who continued HCQ post-ESRD were more likely to be followed by a rheumatologist (26 [87%] vs 17 [61%], p = 0.024), had a higher frequency of documented arthritis (10 [32%] vs 1 [4%], p = 0.005), CNS manifestations (6 [20%] vs 1 [4%], p = 0.055), and concurrent immunosuppressive medication use (22 [71%] vs 12 [43%], p = 0.029). Conclusions Lupus activity may persist after the development of ESRD. New onset arthritis, lupus-related rash, CNS manifestations, low complement and elevated anti-dsDNA may develop. HCQ may be underutilized in patients with evidence of active disease pre- and post ESRD. Careful clinical and serological monitoring for signs of active disease and frequent rheumatology follow up is advised in SLE patients both, pre and post-ESRD.
doi:10.1186/s12882-020-02083-2 pmid:33115441 fatcat:wuzppluikbfuxkyrsndhqzpeoe

Memory Binding Test Predicts Incident Amnestic Mild Cognitive Impairment

Wenzhu B. Mowrey, Richard B. Lipton, Mindy J. Katz, Wendy S. Ramratan, David A. Loewenstein, Molly E. Zimmerman, Herman Buschke
2017 Journal of Alzheimer's Disease  
In the article, the variable called the number of Pairs In the Paired condition (PIP) was mischaracterized, though the main conclusions are not altered. The incorrect PIP measure included in the publication was the number of pairs scored based on single items cued recalled from List 1 and List 2 under the single list recall condition, not the number of pairs recalled under the paired condition. Reanalysis was performed. On
doi:10.3233/jad-179003 pmid:28598853 fatcat:o2exn4m4fncvlod5nkynandtbq

Memory Binding Test Predicts Incident Amnestic Mild Cognitive Impairment

Wenzhu B. Mowrey, Richard B. Lipton, Mindy J. Katz, Wendy S. Ramratan, David A. Loewenstein, Molly E. Zimmerman, Herman Buschke, Josep Garre-Olmo
2016 Journal of Alzheimer's Disease  
In the article, the variable called the number of Pairs In the Paired condition (PIP) was mischaracterized, though the main conclusions are not altered. The incorrect PIP measure included in the publication was the number of pairs scored based on single items cued recalled from List 1 and List 2 under the single list recall condition, not the number of pairs recalled under the paired condition. Reanalysis was performed. On
doi:10.3233/jad-160291 pmid:27540964 fatcat:xwfnfqtthzhnxhdz7k26k3ugwq

MOESM1 of Convalescent Plasmodium falciparum-specific seroreactivity does not correlate with paediatric malaria severity or Plasmodium antigen exposure

Anne Kessler, Joseph Campo, Visopo Harawa, Wilson Mandala, Stephen Rogerson, Wenzhu Mowrey, Karl Seydel, Kami Kim
2018 Figshare  
Additional file 1. Consort diagram of patient recruitment and study design. All cases were recruited from QECH in Blantyre, Malawi. Cases were included in the study if they attended their assigned 30-day follow-up appointment and fit the comparable age and sex distributions (for adjusted comparison) between groups.
doi:10.6084/m9.figshare.6187754 fatcat:v3bzp65f5zhxfo5n76twpn353u

Scalp EEG Ictal gamma and beta activity during infantile spasms: Evidence of focality

Hiroki Nariai, Jules Beal, Aristea S. Galanopoulou, Wenzhu B. Mowrey, Stephan Bickel, Yoshimi Sogawa, Rana Jehle, Shlomo Shinnar, Solomon L. Moshé
2017 Epilepsia  
Objective-We investigated temporal and spatial characteristics of ictal gamma and beta activity on scalp EEG during spasms in patients with West syndrome (WS) to evaluate potential focal cortical onset. Methods-A total of 1033 spasms from 34 patients with WS of various etiologies were analyzed in video-EEG using time-frequency analysis. Ictal gamma (35-90 Hz) and beta (15-30 Hz) activities were correlated with visual symmetry of spasms, objective EMG (electromyography) analysis, and etiology of
more » ... WS. Results-Prior to the ictal motor manifestation, focal ictal gamma activity emerged from one hemisphere (71%, 24/34) or from midline (26%, 9/34), and was rarely simultaneously bilateral (3%, 1/34). Focal ictal beta activity emerged from either one hemisphere (68%, 23/34) or from midline (32%, 11/34). Onsets of focal ictal gamma and beta activity were most commonly observed around the parietal areas. Focal ictal gamma activity propagated faster than ictal beta activity to adjacent electrodes (median: 65 vs. 170 ms, p<0.01), and to contralateral hemisphere (median: 100 vs. 170 ms, p=0.01). Asymmetric peak amplitude of ictal gamma activity in the centroparietal areas (C3-P3 vs. C4-P4) correlated with asymmetric semiology. On the other hand, the majority of visually symmetric spasms showed asymmetry in peak amplitude and interhemispheric onset latency difference in both ictal gamma and beta activity. Significance-Spasms may be a seizure with focal electrographic onset regardless of visual symmetry. Asymmetric involvement of ictal gamma activity to the centroparietal areas may determine the motor manifestations in WS. Scalp EEG ictal gamma and beta activity may be useful to demonstrate localized seizure onset in infants with WS.
doi:10.1111/epi.13735 pmid:28397999 pmcid:PMC5429878 fatcat:yapxh2h5qvgezb5lf67656ymoi

Tubulointerstitial Damage in Lupus Nephritis: A Comparison of the Factors Associated with Tubulointerstitial Inflammation and Renal Scarring

Alejandra Londoño Jimenez, Wenzhu B. Mowrey, Chaim Putterman, Jill Buyon, Beatrice Goilav, Anna Broder
2018 Arthritis & Rheumatology  
Objective-To characterize and compare the factors associated with tubulointerstitial inflammation (TII) and tubulointerstitial scarring, defined as interstitial fibrosis and/or tubular atrophy (IF/TA), in patients with lupus nephritis (LN). Methods-We identified SLE patients with a renal biopsy consistent with LN between 2005 and 2017. Clinical data was collected from the medical records. Multivariable logistic regression models were fitted to assess factors associated with TII and with IF/TA
more » ... oderate-to-severe vs. none-or-mild). Results-Of 203 LN patients included, 41 patients (20%) had moderate-to-severe TII, 45 (22%) had moderate-to-severe IF/TA and 21 (10%) patients had both. Multivariable logistic regression models showed that moderate-to-severe TII was associated with a shorter disease duration, Black
doi:10.1002/art.40575 pmid:29851285 pmcid:PMC6203636 fatcat:6maprerwmjhy3g634k5nz7fsyy

Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy

Erin E. Sundermann, Anat Biegon, Leah H. Rubin, Richard B. Lipton, Wenzhu Mowrey, Susan Landau, Pauline M. Maki
2016 Neurology  
Objective: To examine sex differences in the relationship between clinical symptoms related to Alzheimer disease (AD) (verbal memory deficits) and neurodegeneration (hippocampal volume/ intracranial volume ratio [HpVR]) across AD stages. Methods: The sample included 379 healthy participants, 694 participants with amnestic mild cognitive impairment (aMCI), and 235 participants with AD and dementia from the Alzheimer's Disease Neuroimaging Initiative who completed the Rey Auditory Verbal Learning
more » ... Test (RAVLT). Cross-sectional analyses were conducted using linear regression to examine the interaction between sex and HpVR on RAVLT across and within diagnostic groups adjusting for age, education, and APOE e4 status.
doi:10.1212/wnl.0000000000002570 pmid:26984945 pmcid:PMC4831033 fatcat:ruivslwvejfgfb3zaxzqw3ow4q

Developing and Evaluating ASTHMAXcel Adventures: A Novel Gamified Mobile App for Pediatric Patients with Asthma

Brian Hsia, Anjani K. Singh, Obumneme Njeze, Emine Cosar, Wenzhu B. Mowrey, Jonathan Feldman, Marina Reznik, Sunit P. Jariwala
2020 Annals of Allergy, Asthma & Immunology  
The ASTHMAXcel mobile application has been linked to favorable outcomes among adult asthma patients. We assessed the impact of ASTHMAXcel Adventures, a gamified, guideline-based, pediatric version on asthma control, knowledge, healthcare utilization, and patient satisfaction. Pediatric asthma patients received the ASTHMAXcel Adventures mobile intervention on-site only at baseline (Visit 1), 4 months (Visit 2) and 6 months (Visit 3). The Asthma Control Test (ACT), Asthma Illness Representation
more » ... ale-Self Administered (AIRS-SR), Pediatric Asthma Impact Survey (PAIS), and Client Satisfaction Questionnaire (CSQ-8) were used to assess asthma control, knowledge, and patient satisfaction. Patients reported the number of asthma-related emergency department (ED) visits, hospitalizations, and oral prednisone use. 39 patients completed the study. The proportion of controlled asthma increased from Visit 1 to Visits 2 and 3 (30.8% vs. 53.9%, p=0.04; 30.8% vs. 59.0%, p=0.02), and largely seen in males. Mean AIRS-SR scores increased from baseline pre to post-intervention, with sustained improvements at Visits 2 and 3 (3.55 vs. 3.76, p=0.0006; 3.55 vs. 3.80, p=0.001; 3.55 vs. 3.99, p=0.0001). PAIS scores improved from baseline to Visits 2 and 3 (43.33 vs 34.08, p=0.0006; 43.33 vs. 31.74, p=0.0001). ED visits and prednisone use significantly decreased from baseline to Visits 2 and 3 (ED: 0.46 vs 0.13, p=0.03; 0.46 vs. 0.02, p=0.02; Prednisone: 0.49 vs 0.13, p=0.02; 0.49 vs. 0.03, p=0.003. Satisfaction was high with mean CSQ ∼30 (out of 32) at all visits. ASTHMAXcel Adventures improved asthma control, knowledge, and quality of life, and reduced ED visits and prednisone use with high satisfaction scores.
doi:10.1016/j.anai.2020.07.018 pmid:32711031 pmcid:PMC7375272 fatcat:7cbbnlwo75c2xl7jbgsgt5gpye

Memory Binding Test Distinguishes Amnestic Mild Cognitive Impairment and Dementia from Cognitively Normal Elderly

Herman Buschke, Wenzhu B. Mowrey, Wendy S. Ramratan, Molly E. Zimmerman, David A. Loewenstein, Mindy J. Katz, Richard B. Lipton
2016 Archives of Clinical Neuropsychology  
We had estimated an age-related annual decline of less than 0.30 point in FCSRT-FR scores using the longitudinal data from 1827 non-demented participants from the EAS (Mowrey et al. 2015) .  ... 
doi:10.1093/arclin/acw083 pmid:27680087 pmcid:PMC5860053 fatcat:xhpwsn4zvfhinhpdkjolsap3fm

Memory Binding Test Distinguishes Amnestic Mild Cognitive Impairment and Dementia from Cognitively Normal Elderly

Herman Buschke, Wenzhu B Mowrey, Wendy S Ramratan, Molly E Zimmerman, David A Loewenstein, Mindy J Katz, Richard B Lipton
2017 Archives of Clinical Neuropsychology  
In this report, which assessed reliability and cross-sectional discriminative validity of the Memory Binding Test (MBT) to distinguish individuals with amnestic Mild Cognitive Impairment (MCI) and dementia from cognitive normal elderly, an error was made in the characterization of the number of Pairs-In-the-Paired (PIP) condition. The incorrect PIP measure included in the publication was the number of pairs scored based on single items cued recalled from List 1 and List 2 under the single list
more » ... ecall condition, not the number of pairs recalled under the paired condition. Reanalysis was performed and main results are summarized here and in the tables below. In the publication, it was recommended that the Total number of Items under the Paired condition (TIP) of the MBT be used as the optimal index. Data on the TIP reported in the publication are correct. Reanalysis of the data using the correct values for PIP shows that PIP and TIP were highly correlated (Pearson's correlation: 0.96). PIP has very good reliability (see revised Table 2 below) and cross-sectional discriminative validity (see revised Fig. 1 and revised Table 4 below) (corrections are noted in red font in the tables). PIP performed almost the same as TIP, but TIP is slightly more reliable. Partial AUC comparisons also showed that TIP had slightly better discriminative validity than PIP in distinguishing dementia from controls and aMCI, compared to single list recall measures, Cued Recall from list 1 (CR-L1) and Cued Recall from list 2 (CR-L2). TIP remains a better measure than PIP probably because that PIP counts only pairs but discards single items correctly recalled under the paired condition and that TIP also has a wider and finer range (0−32) compared to PIP (0−16). The good
doi:10.1093/arclin/acx046 pmid:28981569 fatcat:jcenxqbvmjaijcufcscdh3rynu
« Previous Showing results 1 — 15 out of 30 results